AtriCure (NASDAQ:ATRC) is set to announce its earnings results after the market closes on Monday, February 26th. Analysts expect the company to announce earnings of ($0.21) per share for the quarter.
AtriCure (ATRC) opened at $18.00 on Friday. The company has a debt-to-equity ratio of 0.20, a quick ratio of 1.65 and a current ratio of 2.28. AtriCure has a fifty-two week low of $14.88 and a fifty-two week high of $25.18. The company has a market cap of $626.74, a price-to-earnings ratio of -17.65 and a beta of 0.39.
Several equities analysts have recently commented on ATRC shares. Needham & Company LLC lowered their price target on shares of AtriCure from $26.00 to $25.00 and set a “buy” rating on the stock in a report on Thursday, November 2nd. Canaccord Genuity lowered their price target on shares of AtriCure from $28.00 to $24.00 and set a “buy” rating on the stock in a report on Thursday, November 2nd. ValuEngine cut shares of AtriCure from a “hold” rating to a “sell” rating in a report on Wednesday, November 15th. TheStreet cut shares of AtriCure from a “c-” rating to a “d+” rating in a report on Wednesday, November 29th. Finally, Piper Jaffray Companies restated a “buy” rating and set a $24.00 price target on shares of AtriCure in a report on Sunday, December 10th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and six have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $24.33.
In related news, CFO M. Andrew Wade sold 2,000 shares of the company’s stock in a transaction on Thursday, November 30th. The shares were sold at an average price of $18.41, for a total value of $36,820.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, SVP Justin J. Noznesky sold 4,000 shares of the company’s stock in a transaction on Thursday, February 15th. The stock was sold at an average price of $17.03, for a total transaction of $68,120.00. The disclosure for this sale can be found here. Corporate insiders own 10.00% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “AtriCure (ATRC) Set to Announce Earnings on Monday” was first reported by Transcript Daily and is the property of of Transcript Daily. If you are reading this piece on another website, it was stolen and reposted in violation of U.S. & international copyright and trademark law. The correct version of this piece can be read at https://transcriptdaily.com/2018/02/25/atricure-atrc-set-to-announce-earnings-on-monday.html.
AtriCure, Inc is an atrial fibrillation (Afib) solutions company. The Company develops, manufactures, and sells devices designed primarily for the surgical ablation of cardiac tissue and systems designed for the exclusion of the left atrial appendage. It has various product lines for the ablation of cardiac tissue, including its Isolator Synergy Ablation System, for the treatment of persistent and longstanding persistent forms of Afib in patients undergoing certain open concomitant procedures.
Receive News & Ratings for AtriCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure and related companies with MarketBeat.com's FREE daily email newsletter.